A Cellular Culprit Fuels Pulmonary Hypertension
A new study identifies a key molecular mechanism driving the progression of hypoxic pulmonary hypertension (HPH), a severe cardiovascular complication of chronic low oxygen. Researchers found that the protein Cullin 2 is upregulated in the disease state, where it promotes the Warburg effect—a metabolic shift where cells rely on glycolysis for energy even in the presence of oxygen. This metabolic reprogramming accelerates the proliferation of pulmonary artery smooth muscle cells, leading to vascular remodeling and elevated pulmonary artery pressure. The findings, published in *The American Journal of Pathology*, pinpoint Cullin 2 as a central regulator connecting metabolic dysfunction to pathological vascular changes in the lungs.
Why it might matter to you: This research directly links a specific metabolic pathway to vascular remodeling in pulmonary hypertension, a condition with significant cardiac implications. For cardiology, it suggests that targeting metabolic regulators like Cullin 2 could offer a novel therapeutic strategy to halt disease progression, moving beyond symptomatic management. Understanding this mechanism may also inform risk stratification and the development of biomarkers for patients with heart failure or other conditions predisposing them to pulmonary hypertension.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
